IL1B and atherosclerosis: Data from the Canakinumab Anti-Inflammatory Thrombosis Outcome Study (CANTOS), in which the effect of treatment with the therapeutic monoclonal anti-IL-1β antibody canakinumab on the recurrence of cardiovascular events was tested in a large randomized double-blinded trial, showed that IL-1β neutralization significantly reduced the incidence of cardiovascular events in atherosclerosis patients, suggesting a key role of IL-1β in disease activity [149].